论文部分内容阅读
目的分析发生于卵巢的甲状腺乳头状癌(TCASO)的临床病理特征,探讨其生物学行为及分子机制。方法结合临床病理资料,采用HE及免疫组化染色方法并进行BRAF、RAS基因突变检测,对比研究2例卵巢甲状腺乳头状癌的临床病理、免疫组化及分子遗传学特点。结果 2例均无颈部甲状腺病变,肿瘤境界清楚,滤泡型结构,部分细胞具有甲状腺乳头状癌的细胞核特征。2例免疫组化均呈MC和cyclin D1(+);例1CK19(+),CD56(-);例2 CK19(-),CD56(+)。2例BRAF、RAS突变均为(-)。例2具有卵巢恶性肿瘤典型临床表现。2例随访4~15个月,未复发。结论发生于卵巢的甲状腺乳头状癌与原发于甲状腺的乳头状癌可能有相似的分子生物学发生机制,预后较好。
Objective To analyze the clinicopathological features of papillary thyroid carcinoma (TCASO) in ovary and to investigate its biological behavior and molecular mechanism. Methods Combined with clinicopathological data, HE and immunohistochemical staining methods were used to detect BRAF and RAS gene mutation. The clinicopathological, immunohistochemical and molecular genetic characteristics of 2 patients with papillary thyroid carcinoma were analyzed. Results None of the 2 cases had a thyroid lesion of the neck. The tumor had a clear boundary and follicular structure. Some of the cells had the nucleus characteristics of papillary thyroid carcinoma. Two cases of immunohistochemical showed MC and cyclin D1 (+); cases 1CK19 (+), CD56 (-); Case 2 CK19 (-), CD56 (+). Two cases of BRAF and RAS mutations were (-). Case 2 has the typical clinical manifestations of ovarian cancer. Two cases were followed up for 4 to 15 months without recurrence. Conclusion The papillary thyroid carcinoma in the ovary may have a similar molecular mechanism with papillary carcinoma in the thyroid gland. The prognosis is good.